Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agalimmune Founded to Develop Immunotherapeutics for Cancer

Published: Tuesday, December 03, 2013
Last Updated: Monday, December 02, 2013
Bookmark and Share
Funding will be used to continue the translation of Alphaject™ licensed from UMMS.

Agalimmune Ltd has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours.

The new company has been founded by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP.

Agalimmune is based both in London (Agalimmune Ltd) and California (Agalimmune Inc.). The funding will be used to continue the translation of Agalimmune’s leading immunotherapeutic technology, Alphaject™, licensed from the University of Massachusetts Medical School (UMMS), to the clinic.

Alphaject is based on over 20 years of biomedical research carried out by UMMS Professor of Surgery and Medicine Uri Galili, PhD, who discovered the anti-gal immune response and its role in ‘hyper-acute’ organ rejection.

The Alphaject technology includes methods for treating solid tumours in such a way that the immune system actively rejects them, akin to a non-matched graft or transplant. Tumours are directly injected with the Alphaject compound, to which humans naturally have a high antibody titre.

Alphaject coats the tumour cells in alphagal, thereby presenting a foreign antigen to the immune system. This is thought to bring about a 'hyper-acute rejection' of the tumour, and breaks the immune tolerance shielding the tumour from attack, allowing the immune system to both begin to destroy the tumour immediately and also to confer a long-lasting protection over time in the form of enhanced immune surveillance. The effect is analogous to a personalized cancer vaccine, acting continuously to prevent both metastasis and recurrence.

Mike Westby, CEO of Agalimmune, commented: “The development of immunomodulatory therapies is an exciting and rapidly emerging field, which hopefully will lead to improved anti-cancer treatments for patients. We welcome Loxbridge Research and Animatrix Capital as investors.”

Dr Charles Roberts, MD, CEO of Loxbridge Research, said: "Agalimmune is the first therapeutic investment we have made at a stage when the technology has already been in patients, and we are honoured to be working with proven innovators UMass Medical School and Dr Galili, in furthering this promising treatment toward the eventual benefit of people battling cancer. The investment we are making in the technology represents an upper mid-size in our portfolio, and whilst it will follow our investment model in general we are delighted to welcome in a dedicated and industry-experienced team from the outset, given the relatively late stage of the technology."

“Immunotherapy holds great promise as a potential cancer treatment because it allows the body’s own immune system to identify and eradicate cancer cells,” said Giles Whalen, MD, professor of surgical oncology at UMass Medical School and principal investigator on early clinical trials to develop the Alphaject technology. “One of the great benefits of this approach is that the immune system can seek out and attack even the smallest traces of tumour anywhere in the body. What makes Alphaject so remarkable is that it’s designed to alert the immune system and respond to a specific type of cancer cell. Unlike other immunomodulatory therapies, which may stimulate the immune system to attack cells indiscriminately, this helps ensure healthy cells don’t get mistakenly targeted and destroyed.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agalimmune Licenses KODE Biotech’s FSL Technology
Deal worth up to $31M USD (£21 million GBP).
Friday, June 19, 2015
Scientific News
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
Bacteria Use Ranking Strategy to Fight Off Viruses
Researchers have explained why microbes store virus confrontation information sequentially, with most recent attacks first.
Gene Therapy Technique May Help Prevent Cancer Metastasis
Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
The Genetics of Blood Pressure
Researchers have identifed areas of the genome associated with blood-pressure including 17 previously unknown loci.
Mosquito Genetics Determine Tastes
Study reveals mosuito's preference for human versus animal biting is determined by genetics.
Quadruple Helix DNA Aids Cancer Therapies
Researchers have identified the role that a four-stranded version of DNA may play in the role of cancer progression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!